On-Demand Workforce Solutions Provider WeGoLook® Launches Innovative New Assisted Self-Service App
Oct 03, 2017 12:01 pm UTC| Business
OKLAHOMA CITY, Oct. 03, 2017 -- WeGoLook®, an on-demand workforce solutions provider and subsidiary of Crawford Company®, today announced the launch of its newest product, the YouGoLook™ self-service mobile app....
Oct 03, 2017 12:01 pm UTC| Business
– All patients were alive and event-free at 20 months of age as of the August 7, 2017 data cut-off – – Patients in Cohort 2 continue to demonstrate improvements in motor milestones – SAINT MALO, France, Oct. 03, 2017 ...
Destination Maternity Partners with LYONSCG to Deliver Mobile-First Experiences for Moms-to-Be
Oct 03, 2017 12:01 pm UTC| Business
CHICAGO, Oct. 03, 2017 -- Lyons Consulting Group (LYONSCG), a leading digital agency and global commerce service provider, announced its engagement with Destination Maternity Corporation, the world’s leading maternity...
Oct 03, 2017 12:01 pm UTC| Business
NEW YORK, Oct. 03, 2017 -- Intra-Cellular Therapies, Inc. (NASDAQ:ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today announced the Company has...
Oct 03, 2017 12:01 pm UTC| Business
REHOVOT, Israel and NEW YORK, Oct. 03, 2017 -- AIT Therapeutics Inc. (OTC:AITB), a clinical-stage biopharmaceutical company focused on developing inhaled Nitric Oxide (NO) for the treatment of patients with serious lung...
Mesa Labs Declares Quarterly Dividend
Oct 03, 2017 12:01 pm UTC| Business
LAKEWOOD, Colo., Oct. 03, 2017 -- Mesa Laboratories, Inc. (NASDAQ:MLAB) (we, us, our, “Mesa” or the “Company”) today announced that its Board of Directors has declared a regular quarterly dividend of $0.16 per share of...
Spero Therapeutics Announces Positive Phase 1 Clinical Data From Potentiator Platform
Oct 03, 2017 12:01 pm UTC| Business
CAMBRIDGE, Mass., Oct. 03, 2017 -- Spero Therapeutics, Inc., a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing novel treatments for multi-drug resistant...